Antihypertensive drug Kanarb tops output among local new drugs

공유하기

Boryung Pharmaceutical’s antihypertensive treatment Kanarb marked the largest production among 29 locally developed new drugs in 2017, government data showed Thursday.

According to data from the Ministry of Food and Drug Safety, productions of novel drugs by domestic pharmaceuticals amounted to 184.8 billion won ($164.7 million) last year, up 10.1 percent from 167.8 billion won in 2016.

Among all finished drugs, Handok’s arteriosclerosis treatment Plavix topped the production with 84.5 billion won, stepping up from the No. 2 position last year. GC’s Human Serum Albumin Inj. ranked second with 81 billion won, followed by Samjin Pharm’s Platless with 78.7 billion won.

Among raw drug materials, Celltrion’s Remsima concentrate for solution marked 367.1 billion won output and continued to occupy the No.1 spot from last year. The company’s Truxima concentrate for solution ranked second with 347.3 billion won production, and Herzuma concentrates for solution, third with 96.8 billion won.